Best practices in diagnostic immunohistochemistry: Hepatocellular carcinoma versus metastatic neoplasms

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 11, 2007, Pages 1648-1654

  Kakar, Sanjay ^a,d   Gown, Allen M ^b   Goodman, Zachary D ^c   Ferrell, Linda D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PHENOPATH LABORATORIES   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d VA UCSF   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CARCINOEMBRYONIC ANTIGEN; GLYPICAN 3; HEP PAR 1 ANTIGEN; PROTEIN MOC 31; TUMOR MARKER; UNCLASSIFIED DRUG;

BENIGN TUMOR; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER TUMOR; METASTASIS; NEEDLE BIOPSY; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

ANTIBODIES, NEOPLASM; BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC;

EID: 35948984059     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol. 1993;143:1050-1054.
2. Minervini M, Demetris A, Lee R, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997;10:686-692.
3. Morrison C, Marsh W Jr, Frankel WL. A comparison of CD10 to pCEA, MOC-31 and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol. 2002;15:1279-1287.
4. Fan Z, van de Rijn M, Montgomery K, et al. Hep Par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137-144.
5. Kakar S, Muir T, Murphy LM, et al. Immunoreactivity of Hep Far 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol. 2003;119:361-366.
6. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-1598.
7. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol. 2006;30:1405-1411.
8. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37:1435-1441.
9. Ma CK, Zarbo RJ, Frierson HF Jr, Lee MW. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver. Am J Clin Pathol. 1993;99:551-557.
10. Lau SK, Prakash S, Geller SA, et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33:1175-1181.
11. Niemann TH, Hughes JH, De Young BR. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma. Cancer. 1999;87:295-298.
12. Proca DM, Niemann TH, Porcell AI, DeYoung BR. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver: report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol. 2000;8:120-125.
13. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35:697-710.
14. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol. 1998;29:166-169.
15. Wieczorek TJ, Pinkus JL, Glickman JN, Pinkus GS. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol. 2002;118:911-921.
16. Pan CC, Chen PC, Tsay SH, Chiang H. Cytoplasmic immunoreactivity for thyroid transcription factor-1 in hepatocellular carcinoma: a comparative immunohistochemical analysis of four commercial antibodies using a tissue array technique. Am J Clin Pathol. 2004;121:343-349.
17. Lei JY, Bourne PA, diSant'Agnese PA, Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol. 2006;125:519-525.
18. Wang N, Zee S, Zarbo R, et al. Coordinate expression of cylokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
19. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratins 7, 19, 20 in primary and metastatic carcinomas of the liver. Mod Pathol. 1996;9:901-909.
20. Chu P, Wu E, Weiss L. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
21. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. Histopathology. 2006;49:138-151.
22. Kong C, Appenzeller M, Ferrell L. Utility of CD34 reactivity in evaluating focal nodular hepatocellular lesions sampled by fine needle aspiration biopsy. Acta Cytol. 2000;44:218-222.
23. Krishna M, Lloyd RV, Batts KP. Detection of albumin messenger RNA in hepatic and extrahepatic neoplasms: a marker of hepatocellular differentiation. Am J Surg Pathol. 1997;21:147-152.
24. Maitra A, Murakata LA, Albores-Saavedra J. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Am J Clin Pathol. 2001;115:689-694.
25. Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127:1591-1595.
26. Sano K, Kosuge T, Yamamoto J, et al. Primary hepatic carcinoid tumors confirmed with long-term follow-up after resection. Hepatogastroenterology. 1999;46:2547-2550.
27. Wang J, Dhillon A, Sankey E, et al. Neuroendocrine differentiation in primary neoplasms of the liver. J Pathol. 1991;163:61-67.
28. Murakata L, Ishak K, Nzeako U. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;3:874-881.
29. Avery AK, Beckstead J, Renshaw AA, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210.
30. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'renal cell carcinoma marker'. Am J Surg Pathol. 2001;25:1485-1492.
31. Pan CC, Chen PC, Tsay SH, Ho DM. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol. 2005;13:347-352.
32. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol. 2005;18:535-540.
33. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29:747-754.
34. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10:6612-6621.
35. Renshaw A, Granter S. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Mod Pathol. 1998;11:1160-1164.
36. Tsui W, Colombari R, Bonetti F, et al. Hepatic angiomyolipoma: delineation of unusual morphological variants. Am J Surg Pathol. 1999;23:34-48.
37. Ghorab Z, Jorda M, Ganjei P, Nadji M. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol. 2003;11:330-333.
38. Gornicka B, Ziarkiewicz-Wroblewska B, Wroblewski T, et al. Carcinoma, a fibrolamellar variant - immunohistochemical analysis of 4 cases. Hepatogastroenterology. 2005;52:519-523.
39. Garcia de Davila M, Gonzalez-Crussi F, Mangkornkanok M. Fibrolamellar carcinoma of the liver in a child: ultrastructural and immunohistologic aspects. Pediatr Pathol. 1987;7:319-331.
40. Matsuura S, Aishima S, Taguchi K, et al. 'Scirrhous' type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology. 2005;47:382-390.